1998
DOI: 10.1055/s-0037-1615054
|View full text |Cite
|
Sign up to set email alerts
|

Polymorphism of Platelet Membrane Glycoprotein IIIa: Human Platelet Antigen 1b (HPA-1b/PlA2) Is an Inherited Risk Factor for Premature Myocardial Infarction in Coronary Artery Disease

Abstract: SummaryConflicting results of an association between the human platelet antigen 1b (HPA-1b or PlA2) allele and the risk of myocardial infarction and coronary artery disease have been reported. To assess the reason for this discrepancy, we determined the HPA-1 genotype in 298 men who had undergone coronary angiography, including 124 individuals with myocardial infarction, 83 individuals with coronary artery disease but no history of myocardial infarction, and 91 control patients. Among patients with acute or re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

9
58
0
1

Year Published

2001
2001
2018
2018

Publication Types

Select...
4
3

Relationship

1
6

Authors

Journals

citations
Cited by 79 publications
(68 citation statements)
references
References 32 publications
(29 reference statements)
9
58
0
1
Order By: Relevance
“…Increased PIA2-prevalence in CAD and in patients after myocardial infarction was reported [31,32,33,34,35]. In a prospective nested case control trial within the Physician's Health Study no association was found of the PIA2-prevalence with any thrombotic endpoint at all and this was confirmed by the ECTIM and ARIC studies and by some smaller studies [36,37,38,39,40].…”
Section: Discussionmentioning
confidence: 86%
See 1 more Smart Citation
“…Increased PIA2-prevalence in CAD and in patients after myocardial infarction was reported [31,32,33,34,35]. In a prospective nested case control trial within the Physician's Health Study no association was found of the PIA2-prevalence with any thrombotic endpoint at all and this was confirmed by the ECTIM and ARIC studies and by some smaller studies [36,37,38,39,40].…”
Section: Discussionmentioning
confidence: 86%
“…In a prospective nested case control trial within the Physician's Health Study no association was found of the PIA2-prevalence with any thrombotic endpoint at all and this was confirmed by the ECTIM and ARIC studies and by some smaller studies [36,37,38,39,40]. Others seem to resolve these striking differences by their suggestion that PIA2-prevalence does not act as a risk factor per se, but strongly determines the thrombogenic reactivity of the circulating platelets [32]. This concept is attractive, since it addresses platelet hyperreactivity super-imposed to coronary atherosclerosis to act as the final mechanism which translates risk factor-dependent vessel wall morphology into blood-dependent thrombotic infarction.…”
Section: Discussionmentioning
confidence: 96%
“…The PL A2 polymorphism has been identi®ed in 10À21% of the Caucasian population [38À41]. The presence of the PL A2 allele has been associated with increasing platelet sensitivity to platelet agonists [42] and has been proposed as a hemostatic risk factor associated with arterial thrombotic disease [38,43] and neurological damage [39,44,45]. The reported allele frequency is similar to the frequency of donors exhibiting HIPA, and a DNA analysis was performed using a previously published protocol [41] to determine if a correlation between the PL A2 allele and HIPA exists.…”
Section: Pl A2 Allelementioning
confidence: 99%
“…Specifically, the domain is believed to have a biomechanical role in the allosteric signal transmission across the structure (21). The human platelet antigen-1 (HPA-1) polymorphism of the β 3 gene of α IIb β 3 arises from a LeuPro exchange at residue 33 of the mature β3 subunit (22,24), resulting in Leu33 (HPA-1a) or Pro33 (HPA-1b) platelets. This amino acid exchange, located within the PSI domain, leads to an inherited dimorphism that can be of clinical relevance (22).…”
mentioning
confidence: 99%
“…For example, the HPA-1b allele was significantly more frequent among young patients with acute coronary syndrome than among agematched healthy subjects (23). In the LURIC trial, an association study including more than 4,000 individuals, we documented that patients with coronary artery disease (CAD) 1 , who are carriers of the HPA-1b allele, experience their myocardial infarction five years earlier in life than CAD patients who are HPA-1b negative (22,24). In a prospective study on CAD patients undergoing saphenous-vein coronary-artery bypass grafting, we demonstrated that HPA-1b is a hereditary risk factor for bypass occlusion, myocardial infarction, or death after coronary-artery bypass surgery (25).…”
mentioning
confidence: 99%